ACP
DICE

Acuta Capital Partners’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Acuta Capital Partners’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,700
Closed -$136K – 53
2022
Q3 		$136K Buy
+6,700
New +$122K 0.06% 41
2022
Q2 		– Sell
-37,500
Closed -$717K – 54
2022
Q1 		$717K Buy
+37,500
New +$669K 0.34% 36

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acuta Capital Partners's DICE Position: Q4 2022 in Review

Acuta Capital Partners sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q4 2022, closing a stake of 6,700 shares — an estimated $136K sold.

Acuta Capital Partners first reported a position in DICE in Q1 2022 and held it in 2 quarters. The position peaked at $717K in Q1 2022. 109 funds tracked by Wall St. Rank hold DICE as of Q4 2022.

  • Acuta Capital Partners reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 6,700 DICE Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $136K.
  • Acuta Capital Partners first reported a position in DICE Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Acuta Capital Partners's DICE Therapeutics, Inc. Common Stock position peaked at $717K in Q1 2022.
  • 109 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.